Newly Diagnosed Glioblastoma
NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA
A Phase 0 clinical trial to evaluate niraparib, a novel targeted therapy, in patients with newly diagnosed glioblastoma.
Learn More
PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.
Learn More